Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism

被引:51
|
作者
Lodi, Alessia [1 ]
Saha, Achinto [2 ]
Lu, Xiyuan [1 ]
Wang, Bo [1 ]
Sentandreu, Enrique [1 ]
Collins, Meghan [1 ]
Kolonin, Mikhail G. [4 ]
DiGiovanni, John [2 ,3 ]
Tiziani, Stefano [1 ,3 ]
机构
[1] Univ Texas Austin, Dept Nutr Sci, Austin, TX 78712 USA
[2] Univ Texas Austin, Coll Pharm, Div Pharmacol & Toxicol, Austin, TX 78712 USA
[3] Univ Texas Austin, Dell Pediat Res Inst, Austin, TX 78712 USA
[4] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
URSOLIC ACID; MOLECULAR TARGETS; PERILLA-FRUTESCENS; DIETARY AGENTS; CLINICAL-TRIAL; ATP DEPLETION; METABOLOMICS; CURCUMIN; RESVERATROL; CHEMOPREVENTION;
D O I
10.1038/s41698-017-0024-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-throughput screening of a natural compound library was performed to identify the most efficacious combinatorial treatment on prostate cancer. Ursolic acid, curcumin and resveratrol were selected for further analyses and administered in vivo via the diet, either alone or in combination, in a mouse allograft model of prostate cancer. All possible combinations of these natural compounds produced synergistic effects on tumor size and weight, as predicted in the screens. A subsequent untargeted metabolomics and metabolic flux analysis using isotopically labeled glutamine indicated that the compound combinations modulated glutamine metabolism. In addition, ASCT2 levels and STAT3, mTORC1 and AMPK activity were modulated to a greater extent by the combinations compared to the individual compounds. Overall, this approach can be useful for identifying synergistic combinations of natural compounds for chemopreventive and therapeutic interventions.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone
    Zhang, J
    Dai, JL
    Qi, YH
    Lin, DL
    Smith, P
    Strayhorn, C
    Mizokami, A
    Fu, Z
    Westman, J
    Keller, ET
    JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (10): : 1235 - 1244
  • [22] Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models
    Sun, Jinny
    Bok, Robert A.
    DeLos Santos, Justin
    Upadhyay, Deepti
    DeLos Santos, Romelyn
    Agarwal, Shubhangi
    Van Criekinge, Mark
    Vigneron, Daniel B.
    Aggarwal, Rahul
    Peehl, Donna M.
    Kurhanewicz, John
    Sriram, Renuka
    METABOLITES, 2021, 11 (03) : 1 - 21
  • [23] ProstaCaid™ inhibits tumor growth in a xenograft model of human prostate cancer
    Jiang, Jiahua
    Loganathan, Jagadish
    Eliaz, Isaac
    Terry, Colin
    Sandusky, George E.
    Sliva, Daniel
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 40 (05) : 1339 - 1344
  • [24] HEPSIN, a frequent gene expression alteration in prostate cancer inhibits cell growth/invasion in prostate cancer cells
    Srikantan, V
    Valladares, M
    Shaheduzzamen, S
    Vahey, M
    Rhim, JS
    Moul, JW
    Srivastava, S
    JOURNAL OF UROLOGY, 2003, 169 (04): : 159 - 159
  • [25] Combined treatment of fisetin and cabazitaxel significantly inhibits tumor growth and metastasis of prostate cancer cells
    Mukhtar, Eiman
    Adhami, Vaqar M.
    Siddiqui, Imtiaz A.
    Mukhtar, Hasan
    CANCER RESEARCH, 2016, 76
  • [26] Angiogenesis and prostate cancer tumor growth
    Nicholson, B
    Theodorescu, D
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 91 (01) : 125 - 150
  • [27] Tumor metabolism and Docetaxel resistance in prostate cancer
    Ippolito, L.
    Taddei, M. L.
    Marini, A.
    Chiarugi, P.
    FEBS JOURNAL, 2014, 281 : 612 - 612
  • [28] Tumor metabolism and docetaxel resistance in prostate cancer
    Taddei, M.
    Marini, A.
    Ippolito, L.
    Morandi, A.
    Giannoni, E.
    Chiarugi, P.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S65 - S65
  • [29] Tumor metabolism as a driver of lethal prostate cancer
    Kelly, Rachel S.
    Sinnott, Jennifer A.
    Rider, Jennifer R.
    Ebot, Ericka
    Gerke, Travis
    Penney, Kathryn
    Bowden, Michaela
    Loda, Massimo
    Kantoff, Philip W.
    Martin, Neil E.
    Giovannucci, Edward L.
    Pettersson, Andreas Pettersson
    Tyekucheva, Svitlana
    Wilson, Kathryn M.
    Heiden, Matthew Vander
    Mucci, Lorelei A.
    CANCER RESEARCH, 2015, 75
  • [30] Osteoprotegerin treatment inhibits the growth of lytic prostate cancer lesions in bone
    Seibel, MJ
    Blair, JM
    Perryman, LA
    Pwint, HY
    Lelliott, J
    De Winter, J
    Russell, PJ
    Dunstan, CR
    BONE, 2005, 36 : S221 - S222